Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)
16 juil. 2024 09h26 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presented today studies supporting potential use of its novel drug IRX4204 for treatment of amyotrophic lateral sclerosis (ALS)
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
09 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
08 juil. 2024 20h00 HE
|
Io Therapeutics, Inc.
Io Therapeutics, Inc presented studies in multiple cancers with its novel drug that inhibits tumor growth by promoting tumor infiltrating T-lymphocytes
Io Therapeutics, Inc., Announces Publication of Data on a Novel Compound Promoting Anti-Cancer Immune Responses
12 sept. 2023 00h43 HE
|
Io Therapeutics, Inc.
SPRING, Texas, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., announced today the publication in Scientific Reports – Nature Publishing Group, of results from studies done with the...
Io Therapeutics, Inc. Reports Data Demonstrating That the Company's Candidate Treatment for Multiple Sclerosis, IRX4204, Promotes Repair of Damaged Myelin
16 sept. 2016 07h00 HE
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwired - Sep 16, 2016) - Io Therapeutics, Inc., today, reported data demonstrating that the company's experimental rexinoid nuclear receptor (RXR) agonist compound, IRX4204,...
Io Therapeutics, Inc. Announces Sponsored Research Agreement With the National Multiple Sclerosis Society Fast Forward Program
03 août 2015 08h00 HE
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwired - Aug 3, 2015) - Io Therapeutics, Inc. announced today the receipt of funding from the National Multiple Sclerosis Society through Fast Forward to support further...
Io Therapeutics, Inc. Announces Collaboration With The Michael J. Fox Foundation for Parkinson's Research for Evaluation of IRX4204 as a Potential Treatment for Parkinson's Disease
26 févr. 2013 13h53 HE
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwire - Feb 26, 2013) - Io Therapeutics, Inc. announced today the initiation of a collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to evaluate...
IRX4204 as a Potential Disease-Modifying Treatment for Alzheimer's Disease
13 sept. 2012 19h30 HE
|
Io Therapeutics, Inc.
SAN FRANCISCO, CA--(Marketwire - Sep 13, 2012) - Io Therapeutics, Inc. announced today the presentation of data from preclinical studies of its Retinoid X Receptor (RXR) agonist compound IRX4204 in...
Io Therapeutics, Inc. Announces Initiation of Dosing in a Phase II Clinical Trial of IRX4204 in Patients With Advanced Prostate Cancer
06 oct. 2011 11h00 HE
|
Io Therapeutics, Inc.
SANTA ANA, CA--(Marketwire - Oct 6, 2011) - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients...